FGF-21与糖尿病和非酒精性脂肪性肝病关系的研究进展

摘要/Abstract

中图分类号:

R587.1

刘婷, 刘建凤. FGF-21与糖尿病和非酒精性脂肪性肝病关系的研究进展[J]. 承德医学院学报, 2020, 37(6): 508-511.

[1] Nishimura T, Nakatake Y, Konishi M, et al.Identification of a novel FGF, FGF-21, preferentially expressed in the liver[J]. Biochim Biophys Acta, 2000, 1492(1): 203-206.
[2] Fisher FM, Maratos FE.Understanding the Physiology of FGF21[J]. Annu Rev Physiol, 2016, 78: 223-241.
[3] Su X, Kong Y, Peng D.Fibroblast growth factor 21 in lipid metabolism and non-alcoholic fatty liver disease[J]. Clin Chim Acta, 2019, 498: 30-37.
[4] Zhang J, Weng W, Wang K, et al.The role of FGF21 in type 1 diabetes and its complications[J]. Int J Biol Sci, 2018,14(9): 1000-1011.
[5] Xu P, Ye X, Zhang Y, et al.Long-acting hypoglycemic effects of PEGylated FGF21 and insulin glargine in mice with type 1 diabetes[J]. J Diabetes Complications, 2015, 29(1): 5-12.
[6] 孙国鹏,叶贤龙,任桂萍,等. 成纤维细胞生长因子21对1型糖尿病动物模型的肝糖代谢影响及机制研究[J]. 生物化学与生物物理进展,2011,38(10):953-960.
[7] Rosell RS, Krarup HT, Bjerre M.FGF21 and glycemic control in patients with T1D[J]. Endocrine, 2019, 65(3): 550-557.
[8] Fu Z, Wang Z, Liu CH, et al.Fibroblast Growth Factor 21 Protects Photoreceptor Function in Type 1 Diabetic Mice[J]. Diabetes, 2018, 67(5): 974-985.
[9] Xie T, So WY, Li XY, et al.Fibroblast growth factor 21 protects against lipotoxicity-induced pancreatic beta-cell dysfunction via regulation of AMPK signaling and lipid metabolism[J]. Clin Sci (Lond), 2019, 133(19): 2029-2044.
[10] Ge X, Chen C, Hui X, et al.Fibroblast growth factor 21 induces glucose transporter-1 expression through activation of the serum response factor/Ets-like protein-1 in adipocytes[J]. J Biol Chem, 2011, 286(40): 34533-34541.
[11] Li S, Wang N, Guo X, et al.Fibroblast growth factor 21 regulates glucose metabolism in part by reducing renal glucose reabsorption[J]. Biomed Pharmacother, 2018, 108: 355-366.
[12] Wang N, Li S, Guo XC, et al.Fibroblast growth factor 21 improves glucose homeostasis partially via down-regulation of Na+-d-glucose cotransporter SGLT1 in the small intestine[J]. Biomed Pharmacother, 2019, 109: 1070-1077.
[13] Yang M, Dong J, Liu H, et al.Effects of short-term continuous subcutaneous insulin infusion on fasting plasma fibroblast growth factor-21 levels in patients with newly diagnosed type 2 diabetes mellitus[J]. PLoS One, 2011, 6(10): e26359.
[14] Li H, Wu G, Fang Q, et al.Fibroblast growth factor 21 increases insulin sensitivity through specific expansion of subcutaneous fat[J]. Nat Commun, 2018, 9(1): 272.
[15] Wang N, Xu TY, Zhang X, et al.Improving hyperglycemic effect of FGF-21 is associated with alleviating inflammatory state in diabetes[J]. Int Immunopharmacol, 2018, 56: 301-309.
[16] Wang N, Zhao TT, Li SM, et al.Fibroblast Growth Factor 21 Exerts its Anti-inflammatory Effects on Multiple Cell Types of Adipose Tissue in Obesity[J]. Obesity (Silver Spring), 2019, 27(3): 399-408.
[17] Shao M, Yu L, Zhang F, et al.Additive protection by LDR and FGF21 treatment against diabetic nephropathy in type 2 diabetes model[J]. Am J Physiol Endocrinol Metab, 2015, 309(1): E45-E54.
[18] Jung CH, Jung SH, Kim BY, et al.The U-shaped relationship between fibroblast growth factor 21 and microvascular complication in type 2 diabetes mellitus[J]. J Diabetes Complications, 2017, 31(1): 134-140.
[19] Yafei S, Elsewy F, Youssef E, et al.Fibroblast growth factor 21 association with subclinical atherosclerosis and arterial stiffness in type 2 diabetes[J]. Diabetes Metab Syndr, 2019, 13(1): 882-888.
[20] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018更新版)[J]. 中华肝脏病杂志,2018,26(3):195-203.
[21] Tilg H, Moschen AR.Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis[J]. Hepatology, 2010, 52(5): 1836-1846.
[22] Tucker B, Li H, Long X, et al.Fibroblast growth factor 21 in non-alcoholic fatty liver disease[J]. Metabolism, 2019, 101: 153994.
[23] Li H, Wu G, Fang Q, et al.Fibroblast growth factor 21 increases insulin sensitivity through specific expansion of subcutaneous fat[J]. Nat Commun, 2018, 9(1): 272.
[24] Kralisch S, Fasshauer M.Fibroblast growth factor 21: effects on carbohydrate and lipid metabolism in health and disease[J]. Curr Opin Clin Nutr Metab Care, 2011, 14(4): 354-359.
[25] Potthoff MJ, Inagaki T, Satapati S, et al.FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response[J]. Proc Natl Acad Sci USA, 2009, 106(26): 10853-10858.
[26] Lee JH, Kang YE, Chang JY, et al.An engineered FGF21 variant, LY2405319, can prevent non-alcoholic steatohepatitis by enhancing hepatic mitochondrial function[J]. Am J Transl Res, 2016, 8(11): 4750-4763.
[27] Liu X, Zhang P, Martin RC, et al.Lack of fibroblast growth factor 21 accelerates metabolic liver injury characterized by steatohepatities in mice[J]. Am J Cancer Res, 2016, 6(5): 1011-1025.
[28] Gaich G, Chien JY, Fu H, et al.The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes[J]. Cell Metab, 2013, 18(3): 333-340.
[29] Sanyal A, Charles ED, Neuschwander-Tetri BA, et al.Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue,in patients with non-alcoholic steatohepatitis:a randomised, double-blind, placebo-controlled, phase 2a trial[J]. Lancet, 2019, 392(10165): 2705-2717.

FGF-21与糖尿病和非酒精性脂肪性肝病关系的研究进展

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	生庆海, 何双宁, 翟一静, 周慧敏, 李增宁, 孙延国. 智者“三控”教你如何预防糖尿病[J]. 承德医学院学报, 2021, 38(5): 445-448.
[2]	刘扬, 靳英丽, 李莉. 银杏叶提取物对糖尿病肾病的作用分析[J]. 承德医学院学报, 2021, 38(4): 306-308.
[3]	阮鸿娇, 葛婷, 胡万祥, 李金尧, 宋成军, 陈志宏. 线粒体动力学、炎症与2型糖尿病[J]. 承德医学院学报, 2021, 38(3): 234-238.
[4]	伍文耀, 何清香, 陈秋芳, 李德海. 2型糖尿病患者馒头餐前后血清人神经肽水平的变化[J]. 承德医学院学报, 2021, 38(1): 16-19.
[5]	李广涛. 糖尿病合并尿路感染清洁中段尿细菌分离培养与分析[J]. 承德医学院学报, 2020, 37(6): 481-483.
[6]	路存英. 个案管理优势模式在糖尿病视网膜病变患者护理中的应用[J]. 承德医学院学报, 2020, 37(5): 400-401.
[7]	林坚, 朱忠华, 宋湘穗. T2DM并发代谢性炎症综合征危险因素分析[J]. 承德医学院学报, 2020, 37(4): 294-295.
[8]	李东哲, 王丹丹, 蔡明, 田甜, 杨东浩, 张宏. 糖尿病肾病影响因素及相关信号通路研究进展[J]. 承德医学院学报, 2020, 37(4): 333-336.
[9]	王楠, 朱红涛, 刘晓燕. 网膜素-1、内脂素、谷氨酰转肽酶与2型糖尿病患者CIMT的相关性[J]. 承德医学院学报, 2020, 37(3): 198-200.
[10]	张银广, 王佳宇, 李朴涵, 吴合亮, 王鹏, 刘东慧. 2型糖尿病大鼠肝脏IRS-1的变化及丝胶的调节作用^*[J]. 承德医学院学报, 2020, 37(2): 101-104.
[11]	黎玉莲. 日记式心理干预结合回授法健康教育在妊娠期糖尿病患者中的应用[J]. 承德医学院学报, 2020, 37(2): 142-143.
[12]	宋妤轩, 史硕, 阮鸿娇, 葛婷, 宋成军, 陈志宏. AMPK在糖尿病肾病发生发展中的作用^*[J]. 承德医学院学报, 2020, 37(2): 161-165.
[13]	王海生, 罗艾静, 李艳. GDM产妇剖宫产术前应用钠钾镁钙葡萄糖注射液的价值分析[J]. 承德医学院学报, 2020, 37(1): 12-14.
[14]	王胜强. 肥胖型男性2型糖尿病患者性激素和骨钙素水平的变化及其与IR的相关性[J]. 承德医学院学报, 2020, 37(1): 25-27.
[15]	付丹丹. 结构式团体心理干预对2型糖尿病患者心理状态和治疗依从性的影响[J]. 承德医学院学报, 2019, 36(6): 502-504.